NOD2 Antibody

Definition and Context

The NOD2 antibody is a research tool designed to detect and study the Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a critical intracellular pattern recognition receptor (PRR) involved in immune responses. NOD2 recognizes bacterial peptidoglycan components, such as muramyl dipeptide (MDP), and activates downstream signaling pathways like NF-κB to trigger inflammatory and antimicrobial responses .

Structure and Function of NOD2

• Protein Domains:

  • CARD Domains: Two caspase recruitment domains (CARDs) at the N-terminus mediate interactions with signaling molecules (e.g., RIP2) .

  • NOD Domain: Facilitates protein oligomerization upon ligand binding .

  • Leucine-Rich Repeats (LRRs): 11 LRRs at the C-terminus enable recognition of bacterial ligands .

• Immunogenic Epitopes: Antibodies typically target the CARD or LRR regions, with epitopes such as the CARD15 (Q9HC29) sequence .

Applications in Research and Diagnostics

Research Findings

• Infectious Disease: NOD2 antibodies are used to study bacterial pathogenesis (e.g., M. tuberculosis) and viral infections (e.g., RSV), where NOD2 acts as a viral PRR .

• Cancer Immunology: NOD2 agonists enhance antibody-mediated phagocytosis in chronic lymphocytic leukemia (CLL), improving therapeutic antibody efficacy .

• Inflammatory Bowel Disease (IBD): NOD2 mutations correlate with Crohn’s disease susceptibility, with antibodies aiding in diagnostic studies .

Regulatory Regions and Critical Residues

• CARD Domain Mutations: Residues Q31H, E69K, and R180K in CARD1/CARD2 disrupt NF-κB activation, highlighting critical binding sites .

• LRR Mutations: Polymorphisms in LRR regions (e.g., R702W, G908R) impair ligand recognition and are linked to IBD .

Challenges and Future Directions

• Cross-Reactivity: Predicted reactivity with non-human species (e.g., pig, bovine) requires validation .

• Therapeutic Potential: NOD2 agonists are being explored as adjuvants for antibody therapies in oncology .